SCHEMBL30228248

SCHEMBL30228248

Cc1ccccc1-c1cc(=O)oc2cc(O)ccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 10/20 0.70
▸ CA9 Q16790 10/20 0.70
▸ HSD17B3 P37058 4/20 0.67
▸ AKR1B1 P15121 2/20 0.67
▸ MAOB P27338 2/20 0.67
▸ ALDH2 P05091 1/20 0.67
▸ MAOA P21397 1/20 0.67
▸ SORD Q00796 1/20 0.67
▸ KDM4E B2RXH2 5/20 0.65
▸ ALDH1A1 P00352 5/20 0.65
▸ HPGD P15428 4/20 0.65
▸ HSD17B10 Q99714 3/20 0.65
▸ GAA P10253 2/20 0.65
▸ LMNA P02545 2/20 0.65
▸ CYP1A2 P05177 1/20 0.65
▸ GLA P06280 1/20 0.65
▸ CYP2C9 P11712 1/20 0.65
▸ UGT1A1 P22309 1/20 0.65
▸ CASP1 P29466 1/20 0.65
▸ KDR P35968 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22431749 1.00 CA12 (0.70) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL30227989 0.87 KDM4E (0.59) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL14424515 0.86 CA12 (0.75) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL30228211 0.85 CA12 (0.67) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL28585333 0.85 CA12 (0.74) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL20848062 0.83 CA12 (0.67) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL5691199 0.83 KCNA3 (0.62) CA12CA9MAOAKDM4EALDH1A1
SCHEMBL30228412 0.83 KCNA3 (0.62) CA12CA9MAOAKDM4EALDH1A1
SCHEMBL22431782 0.82 CA12 (1.00) CA12CA9HSD17B3AKR1B1MAOB
SCHEMBL20848068 0.82 CA12 (0.70) CA12CA9HSD17B3AKR1B1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034340-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed
WO-2023034339-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM CA12 4755/4885CA9 4824/4885HSD17B3 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback